Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by equities research analysts at Robert W. Baird from a “neutral” rating to an “outperform” rating in a report released on Friday. The analysts noted that the move was a valuation call.

Other equities analysts have also recently issued reports about the stock. BTIG Research reissued a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. Guggenheim reissued a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, October 23rd. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Citigroup reissued a “buy” rating and issued a $480.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, November 13th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus target price of $463.19.

Shares of Regeneron Pharmaceuticals (REGN) opened at $336.38 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.14 and a quick ratio of 3.07. The company has a market cap of $37,680.00, a price-to-earnings ratio of 32.59, a P/E/G ratio of 1.22 and a beta of 1.47. Regeneron Pharmaceuticals has a 12-month low of $314.99 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $1.05. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. Regeneron Pharmaceuticals’s revenue was up 28.9% compared to the same quarter last year. During the same period in the previous year, the company posted $3.04 EPS. equities analysts forecast that Regeneron Pharmaceuticals will post 14.13 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC boosted its position in shares of Regeneron Pharmaceuticals by 495.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after buying an additional 307 shares in the last quarter. Advisory Services Network LLC boosted its position in shares of Regeneron Pharmaceuticals by 147.0% in the 4th quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 266 shares in the last quarter. Vident Investment Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $200,000. Virtu KCG Holdings LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $206,000. Finally, AE Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $206,000. 65.69% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals (REGN) Upgraded at Robert W. Baird” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/02/11/regeneron-pharmaceuticals-regn-upgraded-at-robert-w-baird.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.